Fred_Kadiddlehopper, that may be several things.
One is the recount as explained in the link.
Another could be a merger or acquisition
Yet another is the mere public offer for acquisition or buyout EVEN if not accepted by the company.
Finally some key news that drives the PPS up on its own and forces many short positions into margin calls or stop-losses. Actually, the last revelations of Helen kind of paved the way towards such future event.
The value for HALO to be able to extend its protection under IP for a same product in a growing market (SC administration of a drug with all comfort and time advantages) is very important. Mainly Merck works on competing technology and has an interest to slow down Enhanze by buying licenses for candidates and letting them rot. But now that J&J Janssen drives up the speed things may change. If one has it the others want it to and HALO is always a better partner then buying from your competitor.
So, the news of a rHu with better temperature properties combined with a demonstration by numbers of the years just before that announcement (when it is approved) showing the effective market growth for SC and HALO's market share in it, could be such event.
In the mean time HALO has a share buyback program that actually contributes in the rocket fuel because they reduce the number of outstanding shares and take away all outlook on forms of share issuing (or comparable such as when Notes are issued with buy rights of stock at pre-fixed prices) that could be used to close open short positions.
In that aspect HALO has an advantage on CDMO, however, if CDMO would start paying dividends in a couple of years then that will also lock shares on shelfs and reduce even retail liquidity.
AIMO
News 
Market Data 
Discover 
AI
